Get started

Biotech

Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic. The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline. Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:BIIBLong
by Investing_Fellow
Acadia: Stochastic Oscillator UpturnStochastic Oscillator shows upturn for Acadia. Ichimoku Cloud support is very important in this case since today's session is not breaking it and could demonstrate positive trend force. Please note that biotech companies present high uncertainty. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:ACADLong
by Investing_Fellow
Can SNCA Manage To Break Above Previous ResistanceGreat news and all but can SNCA pull from a technical perspective ? "The patent is for the “Transplantation of human neural cells for treatment of neurodegenerative conditions.” Could this be the next step in developing its NSI-566 treatment? Why I say this is because the treatment is specifically designed around neural stem cells. This is developing as things just began to unfold later in the afternoon. However, it could become one of the penny stocks to watch this month." Source: Are Penny Stocks Profitable? 4 Names To Know Now
S
by PennyStocks101
2
EDIT - EDITAS Genetics time to accumulate and play bounceHello all, Notice MACD, RSI and 50 day MA trends for EDIT. I am planning to accumulate calls this week and some last week to play the bounce signaled by RSI and MACD into the JPM healthcare conference on the 15th where these biotechs present promising results and play pop. Plus biotech is a risky defensive bet - mutually exclusive of Iran - these biotechs are still getting bought out and FDA is approving new drugs like candy.
NASDAQ:EDITLong
by ketokat
CYDY headed toward 1.60 next for wave 5 of I toward stratosphereCytodyn is a 9-year old biotech startup nearing FDA approval for Leronlamib, a humanized monoclonal antibody that's shown no side effects with over 800 AIDS patients through a Phase 3 HIV combo-therapy trial. But Leronlamib is also showing broad efficacy in early trials for HIV monotherapy, HIV prevention, blocking metastasis of many cancers, graft vs host disease, and fatty liver disease (NASH). It was tremendously undervalued until mid-December when it signed an $87 million HIV licensing and commercialization that has stabilized its financing and launched price in a strong up-channel. Submission of BLA application to FDA for HIV combo therapy is imminent in January, which should allow for FDA approval and first sales in 2020. Leronlamib has the potential to transform treatment of several major diseases. Disclosure: I am heavily long.
OTC:CYDYLong
by pythagoras
1
Insider confidence in Adial Pharmaceuticals bodes wellAs Adial Pharmaceuticals advances its Phase 3 clinical trial of AD04 for the treatment of alcohol use, insiders are showing confidence in the company. Today they appointed Mark Howard Peikin as chief strategy officer, and he took the position without a salary. Instead, he accepted a stock option as his sole compensation plan. Chief medical officer Johnson A. Bankole also just acquired over 3,000 shares, perhaps as part of his own compensation plan. If AD04 succeeds in clinical trials, it could be a very profitable drug.
NASDAQ:ADILLong
by ChristopherCarrollSmith
Exelixis made a long-awaited trend line crossI've been waiting on this trend line cross in Exelixis for quite a while now. It's been getting lots of analyst upgrades, and the valuation has been looking better and better. I actually bought some of this in anticipation of the break yesterday, so I'm in the green today. Exelixis's valuation got a 99/100 score from S&P Capital IQ. It has an attractive P/E of 8. There was an insider sale by the senior vice president on October 10, which is a little worrying, but the stock held its price over the last few days, and this trend line breach means the stock should be bullish for the near future.
NASDAQ:EXELLong
by ChristopherCarrollSmith
2
Things are looking up for Johnson & JohnsonJohnson & Johnson beat Wall Street's earnings expectations yesterday and raised its full-year guidance. The company has also been steadily settling opioid lawsuits, with another settlement rumored to be in the works soon. JNJ is rated highly undervalued by S&P Capital IQ, and its post-earnings run looks to be the slow, steady kind rather than a big spike. That's what I like to see. I've picked up a little JNJ and plan to ride it up to at least the 139.50 resistance level. I'm considering a long-term hold, although the political risk makes me cautious about this sector going into an election year.
NYSE:JNJLong
by ChristopherCarrollSmith
KIN Bioscience- accumulate and play bounce into 2020 MACD RSI MAHello team, KIN has momentum going into 2020 - 1) biotech 2) biotech focused on pets and animals! 3) small cap - 330 million look for a double in a year or two or Aquisition. 4) chart hit a solid bottom in mid Nov 2019 with nice buying and selling action in a strong uptrend kissing and bouncing off the 20 day MA - also importantly this stock has spent very few days below 20 day MA in past couple months. Technically it seems MACD and RSI will fall slightly to flush out the stock around -2 or -3 % by/on this Friday 3 Jan 2020 and keeping an eye on these indicators - I would load up on the stock from -1 to -2.5 % so from like $8.41 to $8.33 on Friday and play the bounce for the first real week of 2020 when volume comes back into the market. This could be a nice entry point for a multi month trade if KIN takes off or trade it for a week and take a plus %10 with chance that small cap stock skyrockets 20+ with biotech momentum from FDA etc... I would give up on the trade if the MACD and RSI fall below those levels and fail to show a clear turnaround by like Wednesday of the following week. also a stop loss at $8.28. This looks like a nice gamble with roughly %3 max loss with upside of a highly probably +5% on bounce and a less probable 10% bounce and also a slight single digit chance the stock flexes for 20%+ as these well played biotech tend to do - especially lately cheeeeers - I will be buying Thursday and Friday of this week if the stock is down -1% or the MACD and RSI show a clear reversal with positive gains in stock - then just hop in and play the trade for a longer period of time with by and hold. Just sell the stock higher
KLong
by ketokat
1
Alexion Pharmaceuticals is outrageously undervaluedAfter noticing some call buying activity in Alexion Pharmaceuticals today, I gave the stock a look. Analysts like Alexion. It has an 8.8/10 analyst summary score and an average price target of about $146.50 (versus the current price of about $113). S&P Global Intelligence rates it 85/100 for quality and 87/100 for financial health. Its growth stability earns a score of 62/100, which is great for a pharmaceutical company. Alexion has a nice, diverse portfolio of products that gives it some resiliency against changes in the demand for any one particular drug. But the most attractive thing about Alexion stock is its valuation. The forward P/E of about 10 is very low for a stock with such extraordinary earnings growth. Analyst forecasts for Alexion's earnings have risen something like 25% over the last two years, but the share price has fallen over the same period. Moreover, Alexion has beaten estimates for every single one of the last 8 quarters. S&P Global Intelligence rates Alexion's valuation 97/100 (extremely undervalued)! Today's headline from DJ Realtime News is, "Elliott Looks Forward to Continuing Dialogue With Alexion in Effort to Close Gap Between Current Share Price and Fundamental Value." Go to YouTube and check out my "Wall Street Petting Zoo" video titled "How to Determine the Fair Value of a Stock." There I describe how to use the Zacks "Price and Consensus" chart to determine the fair value of a stock. By this standard, Alexion is conservatively worth $175 per share.
ALong
by ChristopherCarrollSmith
ABBV remains a strong investment even after its recent runAbbvie has been surging lately after a bullish trend line break, but it remains undervalued at the current price. The analyst summary score for Abbvie is 9.6/10, and the average analyst price target is $92 per share. Personally, I think Abbvie's strong earnings forecast and 5.5% dividend yield justifies $100 per share. Call volume in Abbvie is very bullish today after its cancer drug Imbruvica beat a rival cancer drug in a clinical trial.
NYSE:ABBVLong
by ChristopherCarrollSmith